Pfizer, GBT Agree To Pay Up To $750,000 To Settle Oxbryta Economic Loss Claims
SAN FRANCISCO — Pfizer Inc. and Global Blood Therapeutics have agreed to fund up to $750,000 in reimbursements for certain out-of-pocket purchases of the sickle cell disease drug Oxbryta to settle...To view the full article, register now.
Already a subscriber? Click here to view full article